In vivo regulation of the Alzheimers disease beta-secretase, BACE1

每周有1000名澳大利亚人患上痴呆症。阿尔茨海默病(AD)是导致痴呆症的主要原因。阿尔茨海默病的一个特征是大脑中存在β-淀粉样蛋白(AB)斑块。抗体的蓄积会导致毒性和细胞死亡。我们将使用尖端技术来降低产生抗体的酶(BACE1)的水平。这项研究将提供与抗体体内调控相关的基础信息，并为我们降低人脑中BACE1和抗体的最终目标奠定基础。

Dementia claims 1000 Australians weekly. Alzheimer's disease (AD) is the leading cause of dementia. A hallmark of AD is the presence of beta-amyloid (Ab) plaques in brain. Accumulation of Ab leads to toxicity and cell death. We will use cutting-edge technologies to reduce the level of an enzyme (BACE1) that generates Ab. This study will provide seminal information relating to in vivo regulation of Ab and establish a foundation for our ultimate goal of decreasing BACE1 and Ab in human brain.